Literature DB >> 35960268

Statin contribution to middle cerebral artery blood flow velocity in older adults at risk for dementia.

Stacey E Aaron1, Tsubasa Tomoto2,3, Rong Zhang2,3,4, John P Thyfault5,6,7,8,9, Eric D Vidoni1,9, Robert N Montgomery10, Jeffrey M Burns9, Sandra A Billinger11,12,13,14.   

Abstract

PURPOSE: It is plausible that statins could improve cerebral blood flow through pleiotropic mechanisms. The purpose of this investigation was to assess the contribution of statins to cerebrovascular variables in older adults with dyslipidemia and familial history of dementia. Furthermore, we explored the interaction between statin use and sex due to prevalent bias in statin trials.
METHODS: Middle cerebral artery blood flow velocity (MCAv) was measured using transcranial Doppler ultrasound. Continuous supine rest recordings lasted 8 min. Participants included in analyses were statin (n = 100) or non-statin users (n = 112).
RESULTS: MCAv and cerebrovascular conductance were significantly higher in statin users (p = 0.047; p = 0.04), and pulsatility index (PI) was significantly lower in statin users (p < 0.01). An interaction effect between statin use and sex was present for PI (p = 0.02); female statin users had significantly lower cerebrovascular resistance than the other three groups.
CONCLUSION: In this cross-sectional analysis, statin use was positively associated with cerebrovascular variables in older adults at risk for dementia. Female statin users had significantly higher resting MCAv and cerebrovascular conductance than female non-statin users. The greatest contribution of statin use was the association with reduced cerebrovascular resistance. Given that cerebrovascular dysregulation is one of the earliest changes in Alzheimer's disease and related dementia pathology, targeting the cerebrovasculature with statins may be a promising prevention strategy.
© 2022. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.

Entities:  

Keywords:  Alzheimer’s disease; Cerebral blood flow velocity; Cerebrovascular; Dementia; Statin

Mesh:

Substances:

Year:  2022        PMID: 35960268     DOI: 10.1007/s00421-022-05022-1

Source DB:  PubMed          Journal:  Eur J Appl Physiol        ISSN: 1439-6319            Impact factor:   3.346


  47 in total

1.  Estimating risk curves for first-degree relatives of patients with Alzheimer's disease: the REVEAL study.

Authors:  L Adrienne Cupples; Lindsay A Farrer; A Dessa Sadovnick; Norman Relkin; Peter Whitehouse; Robert C Green
Journal:  Genet Med       Date:  2004 Jul-Aug       Impact factor: 8.822

Review 2.  Stroke in women - from evidence to inequalities.

Authors:  Charlotte Cordonnier; Nikola Sprigg; Else Charlotte Sandset; Aleksandra Pavlovic; Katharina S Sunnerhagen; Valeria Caso; Hanne Christensen
Journal:  Nat Rev Neurol       Date:  2017-07-21       Impact factor: 42.937

3.  Circle of Willis atherosclerosis: association with Alzheimer's disease, neuritic plaques and neurofibrillary tangles.

Authors:  Thomas G Beach; Jeffrey R Wilson; Lucia I Sue; Amanda Newell; Marissa Poston; Raquel Cisneros; Yoga Pandya; Chera Esh; Donald J Connor; Marwan Sabbagh; Douglas G Walker; Alex E Roher
Journal:  Acta Neuropathol       Date:  2006-09-20       Impact factor: 17.088

Review 4.  Age and gender bias in statin trials.

Authors:  S Bandyopadhyay; A J Bayer; M S O'Mahony
Journal:  QJM       Date:  2001-03

Review 5.  New cardiovascular targets to prevent late onset Alzheimer disease.

Authors:  Jurgen A H R Claassen
Journal:  Eur J Pharmacol       Date:  2015-05-15       Impact factor: 4.432

6.  Effects of atorvastatin on cerebral blood flow in middle-aged adults at risk for Alzheimer's disease: a pilot study.

Authors:  Cynthia M Carlsson; Guofan Xu; Zhifei Wen; Jodi H Barnet; Hanna M Blazel; Richard J Chappell; James H Stein; Sanjay Asthana; Mark A Sager; David C Alsop; Howard A Rowley; Sean B Fain; Sterling C Johnson
Journal:  Curr Alzheimer Res       Date:  2012-10       Impact factor: 3.498

7.  Mevastatin, an HMG-CoA reductase inhibitor, reduces stroke damage and upregulates endothelial nitric oxide synthase in mice.

Authors:  S Amin-Hanjani; N E Stagliano; M Yamada; P L Huang; J K Liao; M A Moskowitz
Journal:  Stroke       Date:  2001-04       Impact factor: 7.914

Review 8.  Thematic review series: brain Lipids. Cholesterol metabolism in the central nervous system during early development and in the mature animal.

Authors:  John M Dietschy; Stephen D Turley
Journal:  J Lipid Res       Date:  2004-08       Impact factor: 5.922

9.  MRI-guided SPECT perfusion measures and volumetric MRI in prodromal Alzheimer disease.

Authors:  Georges El Fakhri; Marie Foley Kijewski; Keith A Johnson; Grigoriy Syrkin; Ronald J Killiany; J Alex Becker; Robert E Zimmerman; Marilyn S Albert
Journal:  Arch Neurol       Date:  2003-08

10.  Relation of cerebral vessel disease to Alzheimer's disease dementia and cognitive function in elderly people: a cross-sectional study.

Authors:  Zoe Arvanitakis; Ana W Capuano; Sue E Leurgans; David A Bennett; Julie A Schneider
Journal:  Lancet Neurol       Date:  2016-06-14       Impact factor: 44.182

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.